Grand Pharma’s April 2026 HKEX Filing Shows No Change to 3.55 Billion Issued Shares, Public Float Remains Compliant

Bulletin Express05-04

Grand Pharmaceutical Group Limited (Grand Pharma) filed its Monthly Return for Equity Issuer to Hong Kong Exchanges and Clearing Limited covering the period ended 30 April 2026. The document confirms a stable capital structure with no share movements during the month.

Authorised Capital • Authorised share capital stayed at 100.00 billion ordinary shares with a par value of HKD 0.01, equivalent to HKD 1.00 billion.

Issued Shares • Issued ordinary shares (excluding treasury shares) remained unchanged at 3.55 billion. • The company held no treasury shares.

Public Float • Grand Pharma affirmed compliance with the Main Board’s minimum 25 % public-float requirement as at month-end.

Share-Related Instruments • No share options, warrants, convertibles or other agreements to issue shares were outstanding or exercised during April 2026.

Compliance Confirmation • Company Secretary Victor Foo Tin Chung confirmed on 4 May 2026 that all reporting and regulatory obligations related to issued securities have been duly met.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1193240675?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-05-04 17:10","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1193240675","market":"hk","top_or_hot":-1,"title":"Grand Pharma’s April 2026 HKEX Filing Shows No Change to 3.55 Billion Issued Shares, Public Float Remains Compliant","media":"Bulletin Express","content":"<p>Grand Pharmaceutical Group Limited (Grand Pharma) filed its Monthly Return for Equity Issuer to Hong Kong Exchanges and Clearing Limited covering the period ended 30 April 2026. The document confirms a stable capital structure with no share movements during the month.</p>\n<p>Authorised Capital  \n• Authorised share capital stayed at 100.00 billion ordinary shares with a par value of HKD 0.01, equivalent to HKD 1.00 billion.</p>\n<p>Issued Shares  \n• Issued ordinary shares (excluding treasury shares) remained unchanged at 3.55 billion.  \n• The company held no treasury shares.</p>\n<p>Public Float  \n• Grand Pharma affirmed compliance with the Main Board’s minimum 25 % public-float requirement as at month-end.</p>\n<p>Share-Related Instruments  \n• No share options, warrants, convertibles or other agreements to issue shares were outstanding or exercised during April 2026.</p>\n<p>Compliance Confirmation  \n• Company Secretary Victor Foo Tin Chung confirmed on 4 May 2026 that all reporting and regulatory obligations related to issued securities have been duly met.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Grand Pharma’s April 2026 HKEX Filing Shows No Change to 3.55 Billion Issued Shares, Public Float Remains Compliant</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nGrand Pharma’s April 2026 HKEX Filing Shows No Change to 3.55 Billion Issued Shares, Public Float Remains Compliant\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2026-05-04 17:10</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Grand Pharmaceutical Group Limited (Grand Pharma) filed its Monthly Return for Equity Issuer to Hong Kong Exchanges and Clearing Limited covering the period ended 30 April 2026. The document confirms a stable capital structure with no share movements during the month.</p>\n<p>Authorised Capital  \n• Authorised share capital stayed at 100.00 billion ordinary shares with a par value of HKD 0.01, equivalent to HKD 1.00 billion.</p>\n<p>Issued Shares  \n• Issued ordinary shares (excluding treasury shares) remained unchanged at 3.55 billion.  \n• The company held no treasury shares.</p>\n<p>Public Float  \n• Grand Pharma affirmed compliance with the Main Board’s minimum 25 % public-float requirement as at month-end.</p>\n<p>Share-Related Instruments  \n• No share options, warrants, convertibles or other agreements to issue shares were outstanding or exercised during April 2026.</p>\n<p>Compliance Confirmation  \n• Company Secretary Victor Foo Tin Chung confirmed on 4 May 2026 that all reporting and regulatory obligations related to issued securities have been duly met.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"00512","symbol_name":"远大医药","start_time":0,"source_url":"","article_id":"1193240675","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1193240675","pubTimestamp":1777885827,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"Grand Pharmaceutical Group Limited (Grand Pharma) filed its Monthly Return for Equity Issuer to Hong Kong Exchanges and Clearing Limited covering the period ended 30 April 2026. The document confirms...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"00512":"远大医药"},"translate_title":"远大医药2026年4月向港交所提交的文件显示，35.5亿股已发行股份没有变化，公众持股量仍合规","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"00512":1},"content_text":"Grand Pharmaceutical Group Limited (Grand Pharma) filed its Monthly Return for Equity Issuer to Hong Kong Exchanges and Clearing Limited covering the period ended 30 April 2026. The document confirms a stable capital structure with no share movements during the month.\nAuthorised Capital  \n• Authorised share capital stayed at 100.00 billion ordinary shares with a par value of HKD 0.01, equivalent to HKD 1.00 billion.\nIssued Shares  \n• Issued ordinary shares (excluding treasury shares) remained unchanged at 3.55 billion.  \n• The company held no treasury shares.\nPublic Float  \n• Grand Pharma affirmed compliance with the Main Board’s minimum 25 % public-float requirement as at month-end.\nShare-Related Instruments  \n• No share options, warrants, convertibles or other agreements to issue shares were outstanding or exercised during April 2026.\nCompliance Confirmation  \n• Company Secretary Victor Foo Tin Chung confirmed on 4 May 2026 that all reporting and regulatory obligations related to issued securities have been duly met.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"SGX","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.43.1","shortVersion":"4.43.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1193240675","isCrawlerRequest":true}